These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 20920924)

  • 1. Erythropoietin: will it improve outcome after subarachnoid hemorrhage?
    Macdonald RL
    World Neurosurg; 2010 May; 73(5):463-4. PubMed ID: 20920924
    [No Abstract]   [Full Text] [Related]  

  • 2. Erythropoietin for subarachnoid hemorrhage: is there a reason for hope?
    Grasso G; Tomasello F
    World Neurosurg; 2012 Jan; 77(1):46-8. PubMed ID: 22079816
    [No Abstract]   [Full Text] [Related]  

  • 3. Erythropoietin and subarachnoid hemorrhage.
    Niemelä M; Niemi T; Hernesniemi J
    World Neurosurg; 2010 May; 73(5):461-2. PubMed ID: 20920923
    [No Abstract]   [Full Text] [Related]  

  • 4. Erythropoietin and subarachnoid hemorrhage.
    Grasso G; Sfacteria A
    J Neurosurg; 2010 Mar; 112(3):699-700. PubMed ID: 20192676
    [No Abstract]   [Full Text] [Related]  

  • 5. In vivo evidence that erythropoietin has a neuroprotective effect during subarachnoid hemorrhage.
    Buemi M; Grasso G; Corica F; Calapai G; Salpietro FM; Casuscelli T; Sfacteria A; Aloisi C; Alafaci C; Sturiale A; Frisina N; Tomasello F
    Eur J Pharmacol; 2000 Mar; 392(1-2):31-4. PubMed ID: 10748269
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of recombinant human erythropoietin on cerebral ischemia following experimental subarachnoid hemorrhage.
    Alafaci C; Salpietro F; Grasso G; Sfacteria A; Passalacqua M; Morabito A; Tripodo E; Calapai G; Buemi M; Tomasello F
    Eur J Pharmacol; 2000 Oct; 406(2):219-25. PubMed ID: 11020484
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Erythropoietin for the treatment of subarachnoid hemorrhage: a review.
    Turner JD; Mammis A; Prestigiacomo CJ
    World Neurosurg; 2010 May; 73(5):500-7. PubMed ID: 20920933
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recombinant human erythropoietin. Experimental and clinical applications.
    Nielsen OJ
    Dan Med Bull; 1991 Oct; 38(5):355-70. PubMed ID: 1802621
    [No Abstract]   [Full Text] [Related]  

  • 9. The TREAT study answers a question, not the question.
    Coyne DW
    Am J Kidney Dis; 2008 Sep; 52(3):626-7; author reply 627-8. PubMed ID: 18725019
    [No Abstract]   [Full Text] [Related]  

  • 10. Strategies to optimize the use of erythropoietin and iron therapy in oncology patients.
    Ford PA; Mastoris J
    Transfusion; 2004 Dec; 44(12 Suppl):15S-25S. PubMed ID: 15585001
    [No Abstract]   [Full Text] [Related]  

  • 11. Erythropoietin: regulation of erythropoiesis and clinical use.
    Dessypris EN; Krantz SB
    Adv Pharmacol; 1990; 21():127-47. PubMed ID: 2265125
    [No Abstract]   [Full Text] [Related]  

  • 12. Novel strategies for stimulating erythropoiesis and potential new treatments for anaemia.
    Macdougall IC; Eckardt KU
    Lancet; 2006 Sep; 368(9539):947-53. PubMed ID: 16962885
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Two new drugs. Recombinant "human" erythropoietin (EPO: Erypo, Recormon)].
    Verwiebe R
    Internist (Berl); 1992 Apr; 33(4):279-81. PubMed ID: 1612854
    [No Abstract]   [Full Text] [Related]  

  • 14. Darbepoetin (Aranesp) - A long-acting erythropoietin.
    Med Lett Drugs Ther; 2001 Dec; 43(1120):109-10. PubMed ID: 11740411
    [No Abstract]   [Full Text] [Related]  

  • 15. [Erythropoietin: its biological properties and clinical use].
    Ermolenko VM; Nikolaev AIu
    Ter Arkh; 1990; 62(11):141-5. PubMed ID: 2094979
    [No Abstract]   [Full Text] [Related]  

  • 16. Weighing the hazards of erythropoiesis stimulation in patients with cancer.
    Khuri FR
    N Engl J Med; 2007 Jun; 356(24):2445-8. PubMed ID: 17568023
    [No Abstract]   [Full Text] [Related]  

  • 17. A randomized, placebo-controlled clinical trial of recombinant human erythropoietin in the anemia of prematurity.
    Mentzer WC; Shannon KM; Abels RI; Freeman P; Newton N; Thompson D; Phibbs RH
    Contrib Nephrol; 1991; 88():306-12; discussion 313. PubMed ID: 2040193
    [No Abstract]   [Full Text] [Related]  

  • 18. Darbepoetin alfa and history of thromboembolic events.
    Ferretti G; Felici A; Cognetti F
    J Clin Oncol; 2009 Nov; 27(33):e211; author reply e212. PubMed ID: 19858373
    [No Abstract]   [Full Text] [Related]  

  • 19. Endothelial nitric oxide-mediated Nrf2 activation as a novel mechanism for vascular and neuroprotection by erythropoietin in experimental subarachnoid hemorrhage.
    Genc S; Egrilmez MY; Genc K
    Med Hypotheses; 2006; 67(2):424. PubMed ID: 16707229
    [No Abstract]   [Full Text] [Related]  

  • 20. FDA unveils risk-management program for ESAs.
    Traynor K
    Am J Health Syst Pharm; 2010 Apr; 67(7):508-9. PubMed ID: 20237374
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.